Figure 2.

Different IL-2 based approaches to promote the expansion of regulatory T cells (Treg). A first approach consists of using IL-2, together with other stimuli, to expand ex vivo the Treg cells collected from a patient's tissue culture before transferring these cells to the patient (A). In vivo, IL-2 can be administered subcutaneously at high doses but can be associated with rapamycin to prevent activation of effector T cells (Teff) (B) or given at a low dose for the same reason (C). IL-2-specific monoclonal antibodies can be used to target IL-2 selectively to Treg cells (D).